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Epidemiology of hepatitis B, C and D in
Malawi: systematic review
Alexander J Stockdale1,2* , Collins Mitambo3, Dean Everett1,4, Anna Maria Geretti2 and Melita A Gordon1,2
Abstract
Background: Viral hepatitis is an important public health issue in sub-Saharan Africa. Due to rising mortality from
cirrhosis and hepatocellular carcinoma and limited implementation of screening and treatment programmes, it has
been characterised as a neglected tropical disease. Synthesis of the existing evidence on the epidemiology of viral
hepatitis B, C and D in Malawi is required to inform policy and identify research gaps.
Methods: We searched Pubmed, EMBASE and Scopus for studies reporting the epidemiology of viral hepatitis B, C
and D in Malawi from 1990 to 2018. Articles reporting prevalence estimates were included provided they described
details of participant selection, inclusion criteria and laboratory methods (detection of HBsAg, anti-HCV or anti-HDV
antibody, HCV antigen or HCV RNA or HDV RNA). We assessed study quality using a prevalence assessment
tool. Where appropriate, a pooled prevalence was calculated using a DerSimonian Laird random effects model.
Results: Searches identified 199 studies, 95 full text articles were reviewed and 19 articles were included. Hepatitis B
surface antigen (HBsAg) seroprevalence was assessed in 14 general population cohorts. The pooled prevalence among
adults was 8.1% (95% CI 6.1, 10.3). In 3 studies where HBsAg was stratified by HIV status, no effect of HIV on HBsAg
prevalence was observed (OR 1.2 (95% CI: 0.8, 1.6, p = 0.80)). In a single study of HIV/HBV infected individuals, anti-
hepatitis D antibody (anti-HDV) prevalence was low (1.5%). HCV antibody prevalence (anti-HCV) ranged from 0.7 to
18.0% among 12 cohorts in general populations. Among three studies which used PCR to confirm current infection,
the pooled rate of HCV RNA confirmation among anti-HCV positive individuals was only 7.3% (95% CI: 0.0, 24.3).
Conclusions: Hepatitis B is highly prevalent in Malawi. There is a paucity of epidemiological data from rural
areas where 85% of the population reside, and the Northern region. Priority research needs include large-scale
representative community studies of HBV, HDV and HCV seroprevalence, assessment of children following introduction
of the HBV vaccine in 2002, prevalence estimates of viral hepatitis among individuals with cirrhosis and HCC and data
on HCV prevalence using PCR confirmation, to support a viral hepatitis strategy for Malawi.
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Background
Viral hepatitis is the principal cause of liver cirrhosis
and hepatocellular carcinoma (HCC) in sub-Saharan
Africa [1]. Due to limited availability of screening and
treatment programmes, it has been characterised as a
neglected tropical disease [2]. In contrast with HIV, mal-
aria and tuberculosis, where public health interventions
have resulted in substantial reductions in mortality, viral
hepatitis-associated mortality is rising: cirrhosis and
HCC were the cause of an estimated 3.2% of adult
deaths in 2005, rising to 4% in 2016 [3, 4]. In Malawi,
the cirrhosis-associated mortality rate has been ranked
in the top global decile [5]. Across Southern Africa, an
estimated 50–64% of cases of HCC are attributable to
viral hepatitis, and with limited treatment options out-
comes are poor with an estimated annual mortality to
incidence ratio of 96% [6–8]. HCC has been shown to
occur in a younger age group among individuals in
sub-Saharan Africa and in HBV-associated cases (relative
to HCV-associated cases), contributing to increased
disease impact [9, 10].
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Data on the epidemiology of viral hepatitis are re-
quired to inform an effective public health response. In
the Global Health Sector Strategy on Viral Hepatitis
2016–2021, the World Health Organisation (WHO) has
identified the need to define the national disease burden
and strategically target limited resources to counter the
local epidemic. There is a WHO call for data on trans-
mission and risk factors, to identify specific populations
at risk and to quantify the health burden in terms of cir-
rhosis and hepatocellular carcinoma [11].
The Malawi Ministry of Health (MoH) has resolved to
respond to viral hepatitis in a concerted and strategic
manner. As part of the response, a National Viral Hepa-
titis Unit has been created in the MoH to guide the dir-
ection of policy and practice. In order to consolidate the
current available evidence on epidemiology of viral
hepatitis, identify the gaps in knowledge, practice and
policy, we aimed to conduct a systematic review of all
published epidemiological data on the prevalence of
chronic hepatitis B, C and D in Malawi and identify fur-
ther research needs.
Methods
Searches were performed in Pubmed, Scopus and
EMBASE using the search terms Malawi AND (hepatitis
or hepatitis B or HBV or HBsAg or hepatitis C or HCV
or anti-HCV or HCV antibody or core HCV antigen or
HCVcAg or HCV RNA or hepatitis D or HDV or
anti-HD or anti-HDV or HDV IgG or HDV RNA or
viral hepatitis). (Additional file 1: Table S1) Medical sub-
ject headings [MeSH] in Pubmed and EMBASE the-
saurus tools were employed. Searches were restricted to
publications between 1 Jan 1990 and 1 February 2018
with a search update on 22 June 18, to identify published
data from the past 28 years (Fig. 1).
Data were grouped into two categories: “general popula-
tions” which provided data from potentially representative
community samples, pregnant women, or blood donors;
“HIV positive populations” adults or women, or children
receiving routine HIV care, and “special groups”, compris-
ing populations likely to be unrepresentative of the general
population such as medical inpatients, prisoners or med-
ical students.
Studies reporting detection of hepatitis B surface anti-
gen (HBsAg), or total or IgG anti-hepatitis delta anti-
body (anti-HDV) or HDV RNA among HBsAg positive
people, or anti-hepatitis C antibody (anti-HCV), hepa-
titis C core antigen (HCVcAg) or HCV RNA were in-
cluded, provided they presented details of selection and
inclusion criteria and described the laboratory methods
used.
Data extraction and quality assessment
We conducted this review in accordance with PRISMA
guidelines [12]. We extracted details of study design,
participant characteristics (age and gender distribution,
population group), sampling method, dates, study loca-
tions, laboratory test used and prevalence estimates. A
quality assessment tool for prevalence estimates was
used and study quality was independently evaluated by
two authors (AS, CM) with discordance resolved by
discussion [13].
Statistical analysis
Confidence intervals for prevalence were calculated
using the Wilson method. Pooled seroprevalence for
hepatitis B was calculated with the DerSimonian-Laird
random-effects model with Freeman-Tukey double arc-
sine transformation [14, 15]. A random effects model
was applied due to anticipated heterogeneity. Study het-
erogeneity was assessed using the I2 statistic. Analyses
were performed in Stata release 14.2 (College Station,
TX, USA) using the metaprop package [16].
Fig. 1 Flowchart of literature searches
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Results
The literature search identified 199 studies. Following
removal of duplicates, 95 full-text articles were reviewed
and 19 studies that reported epidemiological data on
hepatitis B, C and D in diverse populations in Malawi
were included (Fig. 1).
Description of included studies
The 19 included studies described a total of HBsAg sero-
prevalence data from 16 different cohorts that were gen-
eral or HIV-positive populations (Table 1; Fig. 2) and
three cohorts from specific unrepresentative subgroups
(Table 2); hepatitis D antibody (anti-HDV) data was
available from a single study (Table 3) and hepatitis C
antibody (anti-HCV) data was available from 15 general
or HIV-positive cohorts (Table 4; Fig. 4) and from four
cohorts describing specific subgroups (Table 5). Four-
teen of 18 studies were from urban centres.
Hepatitis B prevalence
HBsAg seroprevalence estimates ranged from 0.0 to
14.3% in general populations and 3.8 to 16.0% in
Table 1 Hepatitis B surface antigen (HBsAg) seroprevalence in Malawi: published data from 1990 to 2018
Population Ref Year Location Laboratory method Prevalence
(n/total)
Prevalence (%),
(95% CI)
General Populations
Pregnant women [20] 1989–1994 QECH, Blantyre MONOLISA HBsAg ULTRA
(Biorad)
0/70 0.0 (0.0, 5.2)
Pregnant women, at
delivery
[18] 1993–1995 Shire Valley Bioelisa HBsAg (Biokit, S.A.) 12/100 12.0 (7.0, 19.8)
Pregnant women [20] 2004–2008 QECH, Health
Centres Blantyre
MONOLISA HBsAg ULTRA
(Biorad)
16/134 11.9 (7.5, 18.5)
Male workers at
sugar estate
[17] 1998 Nchalo Auszyme monoclonal EIA
(Abbott)
40/280 14.3 (10.7, 18.9)
Community, rural
adults
[20] 2001 Mwanza District MONOLISA HBsAg ULTRA
(Biorad)
7/98 7.1 (3.5, 14.0)
Non-pregnant
women (intravaginal
MTZ gel RCT)
[20] 2003–2005 QECH, Blantyre MONOLISA HBsAg ULTRA
(Biorad)
8/137 5.8 (3.0, 11.1)
HIV-negative partners
in a serodiscordant
couple
[19] 2007–2010 Blantyre Lilongwe HBsAg ELISA NS 26/433 6.0 (4.1, 8.7)
Blood donors [21] 2001 Ntechu HBsAg ELISA NS 13/159 8.2 (4.8, 13.5)
HIV-positive populations
HIV-positive pregnant
women, at delivery
[18] 1993–1995 Shire Valley Bioelisa HBsAg (Biokit, S.A.) 8/50 16.0 (8.3, 28.5)
HIV-positive pregnant
women
[20] 2000–2004 QECH, Blantyre MONOLISA HBsAg ULTRA
(Biorad)
6/156 3.8 (1.8, 8.1)
HIV-positive pregnant
women
[22] 2004–2009 Lilongwe Vitros Chemiluminescence
Immunoassay (Ortho Clinical
Diagnostics)
103/2049 5.0 (4.2, 6.1)
HIV-positive pregnant
women
[23] 2008–2009 Blantyre Murex HBsAg Version 3
with Confirmatory Assay
(Murex Biotech)
27/309 8.7 (6.1, 12.4)
HIV positive: male
workers at sugar estate
[17] 1998 Nchalo Auszyme monoclonal EIA
(Abbott)
32/189 16.9 (12.3, 22.9)
HIV-positive adults [24] 2005 QECH, Blantyre Bioelisa HBsAg (Biokit, S.A.) 20/300 6.7 (4.4, 10.1)
HIV positive adults,
ART starters
[25] 2007–2009 QECH, Blantyre Bioelisa HBsAg (Biokit, S.A.) 133/1117 11.9 (10.1, 13.9)
HIV-positive adults in
sero-discordant couple
[19] 2007–2010 Blantyre Lilongwe HBsAg ELISA NS 26/432 6.0 (4.1, 8.7)
HIV-infected children [26] 2008–2010 Lilongwe Genetic Systems HBsAg 3.0
(Bio-Rad)
2/91 2.2 (0.6, 7.7)
Abbreviations: QECH Queen Elizabeth Central Hospital, Blantyre. This is a tertiary referral hospital, MTZ metronidazole, RCT randomised controlled trial. Biorad:
HBsAg ELISA, Biorad, Hercules, CA, USA; Bioelisa: HBsAg 3.0 Biokit SA Barcelona, Spain; Ortho Clinical Diagnositics: Raritan, New Jersey, United States: Siemens:
ADVIA Centaur, Siemens, Munich, Germany; Abbott: Murex HBsAg, Abbott, Illinois, USA; HBsAg ELISA NS- manufacturer not specified
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HIV positive populations (Table 1). One small study
reporting from HIV positive children aged 3 months
- 15 years (median 36 months) reported seropreva-
lence of 2.2% [95% confidence interval (CI) 0.6, 7.7].
This study did not estimate HBV vaccine efficacy as
the vaccine was introduced in Malawi in 2002 and
both vaccinated and non-vaccinated cohorts were
combined. Pooled estimates of HBsAg seroprevalence
among adult general populations was 7.6% (95% CI
4.6, 11.2) and 8.5 (95% CI 5.7, 11.7) in HIV positive
populations (Fig. 3). The overall pooled estimate of
HBsAg seroprevalence in adults was 8.1% (95% CI
6.1, 10.3).
No significant difference in HBsAg prevalence was
noted between HIV-positive and -negative populations
(p = 0.74). The effect of HIV status on HBV seropreva-
lence was assessed directly in three studies, with a total
of 1484 participants, that tested HBsAg prevalence,
stratified by HIV status within the same population.
These populations comprised male workers at a sugar
factory (n = 469) [17], pregnant women recruited at de-
livery (n = 150) [18] and HIV positive and negative sero-
discordant couples recruited for a randomised control
trial of antiretroviral therapy for prevention of transmis-
sion (n = 865) [19]. Among the three groups, the odds
ratio of HBsAg positivity among HIV positive compared
Fig. 2 HBsAg seroprevalence in Malawi, published data 1990–2018
Table 2 HBsAg seroprevalence among special unrepresentative populations in Malawi: Published data from 1990 to 2018
Population Ref Year Location Laboratory method Prevalence
(n/total)
Prevalence
(%, (95% CI))
Adult medical inpatients [27] 2004 Medical ward, QECH, Blantyre Determine HBsAg Rapid Test (Alere) 34/194 17.5 (12.8, 23.5)
Prisoners [28] 2007 Chichiri Prison, Blantyre HBsAg kit (Abbott) 5/164 3.0 (1.3, 6.9)
Medical students [29] 2013 College of Medicine, Blantyre SD Bioline Rapid Test (Alere) 0/89 0.0 (0.0, 4.9)
Abbreviations: QECH Queen Elizabeth Central Hospital, ART antiretroviral therapy
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Table 3 Published data on hepatitis D seroprevalence in Malawi among HBsAg positive individuals
Population Ref Year Location Method Prevalence (n/total) Prevalence (%, (95% CI))
HIV-HBV infected adults [30] 2007–2009 HIV clinic, QECH Blantyre 1. ETI-AB-DELTAK (Diasorin) 2/133 1.5 (0.4, 5.3)
2. HDV RNA PCR (in-house) 0/133 0.0 (0.0, 2.8)
Table 4 Published data on hepatitis C seroprevalence in Malawi
Population Ref Year Location Method Prevalence
(n/total)
Prevalence (%,
(95% CI))
General Populations
Pregnant women [20] 1989–1994 QECH, Blantyre Anti-HCV (Biorad) 2/70 2.9 (0.8, 9.8)
Pregnant women,
at delivery
[18] 1993–1995 Shire Valley Ortho anti-HCV (Ortho
Diagnostics)
18/100 18.0 (11.7, 26.7)
Pregnant women [20] 2004–2008 QECH, Health
Centres Blantyre
Anti-HCV (Biorad) 8/138 5.8 (3.0, 11.0)
Community, rural
adults
[20] 2001 Mwanza District Anti-HCV (Biorad) 9/99 9.0 (4.9, 16.4)
Non-pregnant
women (intravaginal
MTZ gel RCT)
[20] 2003–2005 QECH, Blantyre Anti-HCV (Biorad) 9/146 6.1 (3.3, 11.3)
Male workers at sugar
estate
[17] 1998 Nchalo Ortho anti-HCV (Ortho
Diagnostics)
35/279 10.0 (7.0, 14.1)
Blood donors [32] 1996 KCH, Lilongwe Anti-HCV EIA (Roche)
Confirmed with Anti-HCV
(Abbott)
4/100 4.0 (1.6, 9.8)
Blood donors [21] 2001 Ntechu 1. Murex anti-HCV 10/148 6.8 (3.7, 12.0)
2. HCV RNA by in-house
PCR
1/140 0.7 (0.1, 3.9)
HIV positive populations
HIV-positive pregnant
women, at delivery
[18] 1993–1995 Shire Valley Ortho anti-HCV (Ortho
Diagnostics)
6/50 12.0 (5.6, 23.8)
HIV-positive pregnant
women
[23] 2008–2009 Blantyre 1. Innotest HCV Ab IV
(Innogenetics),
8/309 2.6 (1.3, 5.0)
2. Versant HCV RNA 1.0
assay (Siemens)
1/309 0.3 (0.1, 1.8)
HIV positive patients [24] 2005 QECH, Blantyre Monolisa HCV Ag-Ab
(Biorad) confirmed with
ADVIA Centaur anti-HCV)
and InnoLIA HCV
immunoassay
(Innogenetics)
17/300 5.7 (3.6, 8.9)
HIV-positive male
workers at sugar estate
[17] 1998 Nchalo Ortho anti-HCV Ab (Ortho
Clinical Diagnostics)
28/280 10.0 (7.0, 14.1)
HIV-positive pregnant
women
[20] 2000–2004 QECH, Blantyre Anti-HCV (Biorad) 8/148 5.4 (2.8, 10.3)
HIV positive adults
starting ART
[31] 2014–15 Lilongwe 1. HCV IgG Architect
(Abbott)
5/227 2.2 (0.9, 5.1)
2. RealTime HCV RNA
(Abbott)
0/227 0.0 (0.0, 1.7)
HIV positive patients
on ART for > 10 years
[33] 2014–16 Chiradzulu OraQuick HCV Rapid
antibody test (Orasure)
2/385 0.5 (0.1, 1.9)
Abbreviations: QECH Queen Elizabeth Central Hospital, HCV hepatitis C virus Biorad: Hercules, CA, USA; Ortho Clinical Diagnostics: Raritan, New Jersey, United
States; Roche: Basel Switzerland; Abbott: Illinois, USA; Innogenetics: Ghent, Belgium; Siemens: Munich, Germany; Orasure: Bethlehem, Pennsylvania, United States
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to HIV negative individuals from within the same popu-
lation was 1.2 (95% CI 0.8, 1.6, p = 0.80), indicating no
evidence of association between HBV infection and HIV
infection status. (Fig. 4).
Studies among three unrepresentative groups deemed
at altered risk of HBV infection: (adult medical inpa-
tients, prisoners and medical students) found HBsAg
prevalence rates of 17.5%, 3.0% and 0% respectively
(Table 2).
Hepatitis D prevalence
A single study was available reporting HDV prevalence
among HIV/HBV co-infected individuals commencing
ART in Blantyre [30] (Table 3). This demonstrated
Table 5 Published data on hepatitis C seroprevalence among special unrepresentative populations in Malawi: Published data from
1990 to 2018
Population Ref Year Location Method Prevalence
(n/total)
Prevalence
(%, (95% CI))
Prisoners [28] 2007 Chichiri Prison, Blantyre Anti-HCV (Biotec) 0/164 0.0 (0.0, 2.3)
Adult inpatients (Dermatology,
Urology)
[32] 1996 KCH, Lilongwe Anti-HCV EIA (Roche) Confirmed
with Anti-HCV (Abbott)
13/333 3.9 (2.3, 6.6)
Adult medical inpatients [27] 2004 Medical ward, QECH,
Blantyre
HCV Ag/Ab (Monolisa, Biorad)
confirmed with Immunoassay
(Innogenetics)
9/202 4.5 (2.4, 8.2)
Malawian women and children
with childhood malignancies
[34] 2006–10 QECH, Blantyre HBV ELISA (MP Biomedicals) Mothers: 2/418 0.5 (0.1, 1.7)
Confirmed by HCV BLOT (MP
Biomedicals)
Children: 1/418 0.2 (0.0, 1.3)
Abbreviations: Biotec: Dorset, United Kingdom; Roche: Basel, Switzerland; Abbott: Illinois, USA; Innogenetics: Ghent, Belgium; MP Biomedicals: California, USAKCH
Kamuzu Central Hospital, QECH Queen Elizabeth Central Hospital, HCV hepatitis C virus
Fig. 3 Forest plot of HBsAg prevalence in general and HIV-positive populations, Malawi 1990–2018
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anti-HDV prevalence of 2/133 (1.5%) but none of the
participants were HDV RNA PCR positive.
Hepatitis C prevalence
Among general populations, anti-HCV prevalence
ranged from 0.7 to 18.0% and among HIV-positive popu-
lations from 0.0 to 12.0%. (Table 4, Fig. 5) Three studies
confirmed active HCV infection using RNA PCR. These
comprised a study of HIV-positive adults commencing
ART in Lilongwe [31], a study of blood donors in
Ntcheu [21] and a study of HIV-positive pregnant
women in Blantyre [23]. In these studies, anti-HCV
prevalence was 2.2, 6.8 and 2.6% respectively but HCV
RNA PCR demonstrated active HCV prevalence of 0, 0.7
and 0.3% respectively, with a pooled rate of HCV RNA
confirmation among anti-HCV positive participants of
7.3% (95% CI 0.0–24.3).
Among four studies assessing HCV prevalence in un-
representative special subgroups comprising: prisoners;
medical inpatients in Blantyre and Lilongwe; and chil-
dren with malignancies and their mothers, the preva-
lence of anti-HCV was 0; 3.9 and 4.5; 0.2 and 0.5%
respectively (Table 5).
Discussion
In this systematic review, we have compiled the existing
epidemiological evidence on HBV, HCV and HDV
prevalence in Malawi and have highlighted a number of
key findings and important knowledge gaps. Data from
studies reporting from general and HIV-infected popula-
tions showed a pooled HBsAg seroprevalence estimate
of 8.1% (95% CI 6.1, 10.3). This finding is in keeping
with regional estimates from Mozambique (8.3%),
Tanzania (7.2%) and Zambia (6.1%) [35]. Our study has
benefitted from the inclusion of significantly more data
than previous estimates for Malawi [35, 36]. We noted
that available data were biased toward the two main
urban centres of Lilongwe and Blantyre, that the North-
ern region was under-represented and that there were
no nationally representative community survey data.
Hepatitis C antibody seroprevalence estimates ranged
from 2.9 to 18% from general or HIV-infected popula-
tions. Among the three available studies that reported
HCV RNA confirmation, only 7.3% of 676 participants
with anti-HCV antibody were confirmed to have HCV
RNA replication. This finding has been consistent with
other cohorts across the region and highlights issues
with using anti-HCV as the basis for obtaining epi-
demiological estimates in the absence of confirmatory
testing [37]. Confirmation of anti-HCV results with PCR
or core HCV antigen testing are required to obtain reli-
able prevalence estimates [38]. Accordingly, due to the
paucity of studies reporting PCR data, a pooled HCV
prevalence estimate was not provided in this review.
Furthermore, an assessment of possible association be-
tween HCV, HBV and HIV infection was not possible
based on the limited data. Based on the available evi-
dence, it is likely that HCV prevalence is low in Malawi,
and was below 1% in all studies using RNA confirmation
[21, 23, 31], but larger representative samples employing
confirmatory PCR testing are required to confirm these
findings. Further work to establish whether false positive
Fig. 4 Odds ratio of HBsAg seropositivity according to HIV status
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anti-HCV antibody tests or failure of HCV RNA assays
to detect local HCV strains is required, particularly in
view of the paucity of available genotypic HCV data
from sub-Saharan Africa [39].
Only a single study reporting HDV prevalence was
available, demonstrating a low rate of anti-HDV among
HIV/HBV co-infected patients in Blantyre (1.5%), with
none of the participants showing replication of HDV RNA
by PCR. This finding is in keeping with available limited
data demonstrating a low rate of HDV seroprevalence
from Southern Africa relative to Central or West Africa,
though the paucity of available data from the Southern
Africa region should be noted [30]. Due to the rapid pro-
gression to fatal liver disease associated with HBV/HDV
superinfection or co-infection, cross-sectional commu-
nity estimates of HDV seroprevalence are unlikely to
reliably estimate the true burden of disease caused by
HDV. Studies of hospitalised patients with well-charac-
terised liver disease are required and will facilitate the
ascertainment of the attributable fraction of viral hepa-
titis to liver disease [40].
There are several limitations in this analysis, highlighted
by our assessment of study quality (Additional file 2: Table
S2). The epidemiological evidence presented in this study
is drawn from predominantly small cohorts studies in di-
verse populations employing convenience sampling. A
striking bias toward urban centres was observed with only
four of 18 included studies drawn from rural areas, despite
an estimated 85% of the Malawian population residing in
rural areas [41]. There were no available data from the
Northern region of Malawi, where 13% of the population
live [41]. To overcome these issues of lack of nationally
representative unbiased community data, the use of the
demographic health survey using dried blood spot
sampling represents a promising solution. Dried blood
spots have excellent diagnostic performance relative
to venous blood sampling for HBsAg and anti-HCV
screening and this method has been recently recom-
mended for large surveys by the WHO [38]. Use of
dried blood spots for hepatitis D screening of the
demographic health survey has recently been used in
Burkina Faso [42], and represent an efficient method
Fig. 5 Prevalence of hepatitis C antibody: published data 1990–2018
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to obtain samples without requiring a cold chain or
venepuncture.
The finding of lack of an association between hepatitis
B seroprevalence and HIV status is in keeping with pre-
vious studies from sub-Saharan Africa [43]. This is likely
due to distinct transmission epidemiology, with hepatitis
B predominantly acquired perinatally or horizontally in
early childhood, and HIV acquired predominantly during
adolescence or adulthood by sexual transmission in
sub-Saharan Africa. By contrast, recent evidence of inci-
dent transmission of HBV in HIV-infected adults has
highlighted the risk of HBV acquisition in adulthood
[44]. Hepatitis B vaccination is provided as a component
of the pentavalent vaccine (also containing, diphtheria,
tetanus, pertussis and Haemophilis influenzae type B) in
the expanded programme of immunisation schedule for
Malawian infants, provided at 6, 10 and 14 weeks since
2002. The Demographic Health Survey 2015–16 esti-
mated 3-dose coverage of the vaccine of 93.0%, with
consistently high coverage exceeding 90%, regardless of
socioeconomic status or geographic location [45]. The
WHO has recently proposed that gathering data on
hepatitis B seroprevalence among a vaccinated cohort
at 5 years of age is a priority in order to generate evi-
dence on the efficacy of HBV vaccination programmes
and this is a priority area for research highlighted by
this review [46].
Conclusions
Hepatitis B is highly prevalent in Malawi with an esti-
mated seroprevalence among the general population
of 8.1%. HCV prevalence was below 1% in three
general population cohorts that used nucleic amplifi-
cation confirmatory testing. There is a need for
representative unbiased community seroprevalence es-
timates of HBV, HDV and HCV prevalence. These
should include confirmatory PCR testing to establish
reliable HCV prevalence estimates. Future studies
examining seroprevalence among community samples,
with a particular focus on rural areas and the North-
ern region, are required. Assessment of the effective-
ness of the hepatitis B vaccination programme
introduced in 2002 and data on HDV prevalence
among HBsAg positive individuals represent further
research priorities. Prevalence estimates of viral hepa-
titis among people with well-characterised liver dis-
ease with cirrhosis and HCC are required to ascertain
the attributable fraction and burden of disease. These
data will help to support a viral hepatitis strategy for
Malawi, facilitate the introduction of screening and
treatment programmes for HBV and HCV and begin
to reverse the current trend of increasing viral
hepatitis-associated mortality.
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